Description:
This tablet is a fixed-dose combination antiretroviral medication containing Tenofovir Disoproxil Fumarate (300 mg), Efavirenz (600 mg), and Emtricitabine (200 mg). It is used in the management of HIV-1 (Human Immunodeficiency Virus) infection. This once-daily regimen simplifies HIV treatment and enhances adherence by combining three potent agents into a single tablet.
Therapeutic Use:
Treatment of HIV-1 infection in adults and adolescents as part of antiretroviral therapy (ART)
Helps suppress the viral load, improve immune response, and reduce the risk of HIV-related complications
Mechanism of Action:
Tenofovir Disoproxil Fumarate and Emtricitabine are nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) that block the reverse transcriptase enzyme, preventing viral replication.
Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that directly inhibits reverse transcriptase through a different mechanism, providing a complementary antiviral effect.
Dosage Form:
Tablet
Prescription Status:
Prescription-only medication
Note:
This medication is not a cure for HIV but plays a critical role in controlling the virus, improving quality of life, and preventing disease progression. It should be used under medical supervision, with regular monitoring of viral load, liver function, and other clinical parameters.
Would you like this description tailored for product packaging, catalog listings, or online pharmacy platforms?
